Palisade Bio Inc

Market Cap

$368M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.74-$0.76 (-30.40%)

Jun 5, 2026

52W High $2.8052W Low $0.54

Company Details

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product...

CEO

—

IPO Date

Dec 20, 2006

Website

www.palisadebio.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$24M

EPS (Diluted)

Free Cash Flow

-$12M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 12, 2026

FY 2025

Mar 20, 2026

Q4 2025

Mar 20, 2026

$0-100.0%

Q3 2025

Nov 10, 2025

Q2 2025

Aug 11, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee